Promising New Treatments for Psoriasis

Table 1

Drugs involved in the treatment of psoriasis.

Drug	Molecular target	Clinical trial phase	Administration route
Infliximab	TNF inhibitor	III	Intravenous
Etanercept	TNF inhibitor	Approved	Subcutaneous
Adalimumab	TNF inhibitor	Approved	Subcutaneous
Certolizumab Pegol	TNF inhibitor	III	Subcutaneous
Ustekinumab	IL-12/IL-23 inhibitor	Approved	Subcutaneous
Apilimod	IL-12/IL-23 inhibitor	II	Oral
Brodalumab	IL-23 inhibitor	III	Subcutaneous
Secukinumab	IL-17 inhibitor	III	Subcutaneous
Ixekizumab	IL-17 inhibitor	III	Subcutaneous
Alefacept	Anti T cell	Approved	Intravenous intramuscular
Apremilast	PDE 4 inhibitor	III	Oral
Sotrastaurin	PKC inhibitor	II	Oral
BMS-582949	P38 MAP inhibitor	II	Oral
Tofacitinib	Jak 3 inhibitor	III completed	Oral

Jak: janus kinase; p38 MAP: p38 mitogen-activated protein kinase; PKC: protein kinase C; PDE4: phosphodiesterase 4.